HC Wainwright Forecasts Evotec’s Q1 Earnings (NASDAQ:EVO)

Evotec SE (NASDAQ:EVO) – Analysts at HC Wainwright dropped their Q1 2025 EPS estimates for Evotec in a report issued on Monday, April 21st. HC Wainwright analyst D. Tsao now forecasts that the company will post earnings per share of ($0.05) for the quarter, down from their prior estimate of ($0.01). The consensus estimate for Evotec’s current full-year earnings is ($0.41) per share. HC Wainwright also issued estimates for Evotec’s Q2 2025 earnings at ($0.06) EPS, Q3 2025 earnings at ($0.05) EPS, Q4 2025 earnings at ($0.05) EPS, FY2025 earnings at ($0.20) EPS and FY2026 earnings at $0.00 EPS.

Evotec Trading Up 3.0 %

Shares of EVO stock opened at $4.09 on Wednesday. The stock’s 50-day moving average is $3.65 and its 200 day moving average is $4.07. Evotec has a 1-year low of $2.84 and a 1-year high of $5.68. The company has a quick ratio of 1.99, a current ratio of 2.09 and a debt-to-equity ratio of 0.43.

Institutional Investors Weigh In On Evotec

A number of hedge funds and other institutional investors have recently bought and sold shares of EVO. Lighthouse Investment Partners LLC purchased a new stake in shares of Evotec during the 4th quarter valued at $166,000. DCF Advisers LLC raised its position in shares of Evotec by 5.9% in the 4th quarter. DCF Advisers LLC now owns 229,871 shares of the company’s stock valued at $956,000 after purchasing an additional 12,816 shares during the last quarter. CSS LLC IL acquired a new stake in Evotec in the 4th quarter worth approximately $50,000. Bank of America Corp DE increased its stake in Evotec by 262.5% during the 4th quarter. Bank of America Corp DE now owns 12,828 shares of the company’s stock valued at $53,000 after purchasing an additional 9,289 shares in the last quarter. Finally, BNP Paribas Financial Markets acquired a new stake in shares of Evotec during the fourth quarter worth $27,000. Hedge funds and other institutional investors own 5.81% of the company’s stock.

About Evotec

Evotec SE operates as drug discovery and development partner for the pharmaceutical and biotechnology industry worldwide. The company is developing pharmaceutical products in various therapeutic areas, such as autoimmune diseases, cancer, CNS diseases, diabetes, fibrosis, immunology, infectious diseases, kidney diseases, liver diseases, pain and inflammation, rare diseases, respiratory diseases, tuberculosis, and women’s health.